These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33906049)

  • 1. Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
    Zhu M; Zhou H; Ma L; Dong B; Zhou J; Zhang G; Wang M; Wang J; Cen S; Wang Y
    Eur J Med Chem; 2021 Aug; 220():113450. PubMed ID: 33906049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Piperidine scaffold as the novel P2-ligands in cyclopropyl-containing HIV-1 protease inhibitors: Structure-based design, synthesis, biological evaluation and docking study.
    Zhou H; Zhu M; Ma L; Zhou J; Dong B; Zhang G; Cen S; Wang Y; Wang J
    PLoS One; 2020; 15(7):e0235483. PubMed ID: 32697773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
    Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
    J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRL-079, a Novel HIV-1 Protease Inhibitor, Is Extremely Potent against Multidrug-Resistant HIV-1 Variants and Has a High Genetic Barrier against the Emergence of Resistant Variants.
    Delino NS; Aoki M; Hayashi H; Hattori SI; Chang SB; Takamatsu Y; Martyr CD; Das D; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
    Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
    ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis and biological evaluation of novel HIV-1 protease inhibitors with pentacyclic triterpenoids as P2-ligands.
    Zhu M; Du XN; Li YG; Zhang GN; Wang JX; Wang YC
    Bioorg Med Chem Lett; 2019 Feb; 29(3):357-361. PubMed ID: 30580917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary SAR and biological evaluation of potent HIV-1 protease inhibitors with pyrimidine bases as novel P2 ligands to enhance activity against DRV-resistant HIV-1 variants.
    Zhu M; Ma L; Zhou H; Dong B; Wang Y; Wang Z; Zhou J; Zhang G; Wang J; Liang C; Cen S; Wang Y
    Eur J Med Chem; 2020 Jan; 185():111866. PubMed ID: 31734023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and biological evaluation of cinnamic and phenylpropionic amide derivatives as novel dual inhibitors of HIV-1 protease and reverse transcriptase.
    Zhu M; Shan Q; Ma L; Wen J; Dong B; Zhang G; Wang M; Wang J; Zhou J; Cen S; Wang Y
    Eur J Med Chem; 2021 Aug; 220():113498. PubMed ID: 33933756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P2 ligands with potent activity against DRV-Resistant HIV-1 variants.
    Meng S; Gao Y; Qiang G; Hu Z; Shan Q; Wang J; Wang Y; Mou J
    Bioorg Med Chem Lett; 2024 Mar; 101():129651. PubMed ID: 38342391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-5-Modified Tetrahydropyrano-Tetrahydofuran-Derived Protease Inhibitors (PIs) Exert Potent Inhibition of the Replication of HIV-1 Variants Highly Resistant to Various PIs, including Darunavir.
    Aoki M; Hayashi H; Yedidi RS; Martyr CD; Takamatsu Y; Aoki-Ogata H; Nakamura T; Nakata H; Das D; Yamagata Y; Ghosh AK; Mitsuya H
    J Virol; 2015 Nov; 90(5):2180-94. PubMed ID: 26581995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
    Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
    Bioorg Med Chem; 2020 Aug; 28(16):115623. PubMed ID: 32690263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Kulkarni S; Anderson DD; Hong L; Baldridge A; Wang YF; Chumanevich AA; Kovalevsky AY; Tojo Y; Amano M; Koh Y; Tang J; Weber IT; Mitsuya H
    J Med Chem; 2009 Dec; 52(23):7689-705. PubMed ID: 19746963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
    Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Design of Highly Potent HIV-1 Protease Inhibitors Containing New Tricyclic Ring P2-Ligands: Design, Synthesis, Biological, and X-ray Structural Studies.
    Ghosh AK; Kovela S; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2020 May; 63(9):4867-4879. PubMed ID: 32348139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A conserved hydrogen-bonding network of P2 bis-tetrahydrofuran-containing HIV-1 protease inhibitors (PIs) with a protease active-site amino acid backbone aids in their activity against PI-resistant HIV.
    Yedidi RS; Garimella H; Aoki M; Aoki-Ogata H; Desai DV; Chang SB; Davis DA; Fyvie WS; Kaufman JD; Smith DW; Das D; Wingfield PT; Maeda K; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3679-88. PubMed ID: 24752271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.